The Evolution of RNA Technology Workshop, Monday 16 October 2023
The Evolution of RNA Technology Workshop
13:00Pre-congress day workshops are OFFSITE at the Alexandre Hotel Fira Congress
The Evolution of RNA
13:00 Panel: How does RNA compare to the other technology platforms?
- The importance of having multiple platform technologies - viral vectors, toxoid, subunit, inactivated.
- Which diseases does it make sense to pursue RNA for and which diseases does it not?
- Can we apply newer technologies to older concepts and platforms in order to revive their use & interest?
Moderator: Hansilla Alaigh, Head of Alliances & Business Operations, Sequris CSL
Prof Jeffrey W. Almond, FMedSci. Visiting Professor of Microbiology, University of Oxford
Pierre Cote, Head of Strategic Partnerships & Innovation Management, mRNA centre of excellence, Sanofi
Dr Maria Elena Bottazzi, Co-Director of Texas Children’s Hospital for Vaccine Development, Baylor College of Medicine
Dr Robbert van der Most, VP, Translational Science, BioNTech
14:00 Panel: How are we improving RNA vaccine technology?
- Next generation RNA modalities
- Development of phospholipid nanoparticles and alternative formulations
- Understanding durability of immune response
- Adjuvants for RNA
- Broadening applicable disease targets
Moderator: Prof Jeffrey W. Almond, FMedSci. Visiting Professor of Microbiology, University of Oxford
Dr Andreas Kuhn, SVP, RNA Biochemistry & CMC Development, BioNTech
Dr Jacqueline Miller, SVP, Therapeutic Area Head - Infectious Disease Development, Moderna
Dr Sudha Chivukula, AVP, Head of Discovery Biology, mRNA Centre of Excellence, Sanofi
Dr Dennis Christensen, Head of Global Research & Development Adjuvant Systems, CRODA
15:00 Panel: What are the remaining challenges for RNA technology?
- Overcoming challenges with manufacturing RNA and cold chain requirements.
- Is RNA compatible with alternative delivery?
- Cost of RNA, global health & access
- Beyond COVID: launching new products and exploring the potential of RNA.
Moderator: Anjalee Khemlani, Senior Reporter, Yahoo! Finance
Dr Alexander Zehnder, CEO, CureVac
Dr Ole F. Olesen, Executive Director, European Vaccine Initiative
Dr Erin Spiegel, Vice President of Clinical and Regulatory Affairs, PharmaJet
Dr Els Torreele, Visiting Fellow, Institute for Innovation and Public Purpose, UCL
WORKSHOP: The Evolution of RNA Technology [OFFSITE]
Pre-congress day workshops are OFFSITE at the Alexandre Hotel Fira Congress
The Evolution of RNA
13:00 Panel: How does RNA compare to the other technology platforms?
- The importance of having multiple platform technologies - viral vectors, toxoid, subunit, inactivated.
- Which diseases does it make sense to pursue RNA for and which diseases does it not?
- Can we apply newer technologies to older concepts and platforms in order to revive their use & interest?
Moderator: Hansilla Alaigh, Head of Alliances & Business Operations, Sequris CSL
Prof Jeffrey W. Almond, FMedSci. Visiting Professor of Microbiology, University of Oxford
Pierre Cote, Head of Strategic Partnerships & Innovation Management, mRNA centre of excellence, Sanofi
Dr Maria Elena Bottazzi, Co-Director of Texas Children’s Hospital for Vaccine Development, Baylor College of Medicine
Dr Robbert van der Most, VP, Translational Science, BioNTech
14:00 Panel: How are we improving RNA vaccine technology?
- Next generation RNA modalities
- Development of phospholipid nanoparticles and alternative formulations
- Understanding durability of immune response
- Adjuvants for RNA
- Broadening applicable disease targets
Moderator: Prof Jeffrey W. Almond, FMedSci. Visiting Professor of Microbiology, University of Oxford
Dr Andreas Kuhn, SVP, RNA Biochemistry & CMC Development, BioNTech
Dr Jacqueline Miller, SVP, Therapeutic Area Head - Infectious Disease Development, Moderna
Dr Sudha Chivukula, AVP, Head of Discovery Biology, mRNA Centre of Excellence, Sanofi
Dr Dennis Christensen, Head of Global Research & Development Adjuvant Systems, CRODA
15:00 Panel: What are the remaining challenges for RNA technology?
- Overcoming challenges with manufacturing RNA and cold chain requirements.
- Is RNA compatible with alternative delivery?
- Cost of RNA, global health & access
- Beyond COVID: launching new products and exploring the potential of RNA.
Moderator: Anjalee Khemlani, Senior Reporter, Yahoo! Finance
Dr Alexander Zehnder, CEO, CureVac
Dr Ole F. Olesen, Executive Director, European Vaccine Initiative
Dr Erin Spiegel, Vice President of Clinical and Regulatory Affairs, PharmaJet
Dr Els Torreele, Visiting Fellow, Institute for Innovation and Public Purpose, UCL
last published: 03/Oct/23 17:27
